Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Share-based Compensation (2019 - 2025)

Pliant Therapeutics (PLRX) has disclosed Share-based Compensation for 7 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 46.24% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.2 million through Dec 2025, down 30.28% year-over-year, with the annual reading at $26.2 million for FY2025, 30.28% down from the prior year.
  • Share-based Compensation for Q4 2025 was $4.5 million at Pliant Therapeutics, down from $6.4 million in the prior quarter.
  • The five-year high for Share-based Compensation was $13.0 million in Q2 2023, with the low at $2.3 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $7.1 million, with a median of $7.4 million recorded in 2024.
  • The sharpest move saw Share-based Compensation surged 506.59% in 2021, then crashed 46.24% in 2025.
  • Over 5 years, Share-based Compensation stood at $2.8 million in 2021, then skyrocketed by 292.16% to $10.9 million in 2022, then decreased by 15.69% to $9.2 million in 2023, then decreased by 8.03% to $8.4 million in 2024, then plummeted by 46.24% to $4.5 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $4.5 million, $6.4 million, and $6.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.